Neuphoria Therapeutics Inc. Other Research and Development Expense
Neuphoria Therapeutics Inc. (NEUP) reported Other Research and Development Expense of $28.75 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherResearchAndDevelopmentExpense · last filed 2026-09-18
- Neuphoria Therapeutics Inc. other research and development expense for the quarter ending 2026-06-30 was $0.00.
- Neuphoria Therapeutics Inc. other research and development expense for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Neuphoria Therapeutics Inc. other research and development expense for the quarter ending 2025-12-31 was $28.75K, a 89.18% increase year-over-year.
- Neuphoria Therapeutics Inc. other research and development expense for the quarter ending 2025-09-30 was $14.40K, a 0.61% increase year-over-year.
- Neuphoria Therapeutics Inc. other research and development expense for fiscal 2026 was $28.75K, a 34.88% decline from fiscal 2025.
- Neuphoria Therapeutics Inc. other research and development expense for fiscal 2025 was $44.15K, a 27.76% decline from fiscal 2024.
- Neuphoria Therapeutics Inc. other research and development expense for fiscal 2024 was $61.11K, a 5.59% decline from fiscal 2023.
- Neuphoria Therapeutics Inc. other research and development expense for fiscal 2023 was $64.73K.
| Period end | Other Research and Development Expense 3 month | Other Research and Development Expense 3 month as first filed | Other Research and Development Expense 6 month | Other Research and Development Expense 9 month | Other Research and Development Expense 12 month | Other Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $0.00 derived: sum of 2 quarters · filed 2026-09-18 | $28.75K derived: sum of 3 quarters · filed 2026-09-18 | $28.75K 10-K · filed 2026-09-18 | ||
| 2026-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | $28.75K derived: sum of 2 quarters · filed 2026-05-15 | $28.75K 10-Q · filed 2026-05-15 | $43.15K derived: sum of 4 quarters · filed 2026-09-18 | ||
| 2025-12-31 | $28.75K 10-Q · filed 2026-02-17 | $28.75K 10-Q · filed 2026-02-17 | $43.15K derived: sum of 3 quarters · filed 2026-09-18 | $59.02K derived: sum of 4 quarters · filed 2026-09-18 | ||
| 2025-09-30 | $14.40K 10-Q · filed 2025-11-14 | $14.40K derived: sum of 2 quarters · filed 2026-09-18 | $30.27K derived: sum of 3 quarters · filed 2026-09-18 | $45.47K derived: sum of 4 quarters · filed 2026-09-18 | ||
| 2025-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $15.87K derived: sum of 2 quarters · filed 2026-09-18 | $31.07K derived: sum of 3 quarters · filed 2026-09-18 | $44.15K 10-K · filed 2026-09-18 | $45.90K 10-K · filed 2025-09-29 | |
| 2025-03-31 | $15.87K 10-Q · filed 2026-05-15 | $31.07K derived: sum of 2 quarters · filed 2026-05-15 | $44.15K 10-Q · filed 2026-05-15 | $60.59K derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $15.20K 10-Q · filed 2026-02-17 | $12.99K 10-Q · filed 2025-02-14 | $28.28K 10-Q · filed 2026-02-17 | $44.72K derived: sum of 3 quarters · filed 2026-02-17 | $59.94K derived: sum of 4 quarters · filed 2026-02-17 | |
| 2024-09-30 | $14.31K 10-Q · filed 2025-11-14 | $29.52K derived: sum of 2 quarters · filed 2025-11-14 | $44.74K derived: sum of 3 quarters · filed 2025-11-14 | $59.94K derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $15.21K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $30.43K derived: sum of 2 quarters · filed 2025-09-29 | $45.62K derived: sum of 3 quarters · filed 2025-09-29 | $61.11K 10-K · filed 2025-09-29 | ||
| 2024-03-31 | $15.22K 10-Q · filed 2025-05-20 | $30.41K derived: sum of 2 quarters · filed 2025-05-20 | $45.90K 10-Q · filed 2025-05-20 | |||
| 2023-12-31 | $15.20K 10-Q · filed 2025-02-14 | $30.68K 10-Q · filed 2025-02-14 | ||||
| 2023-09-30 | $14.00K 10-Q · filed 2024-11-14 | |||||
| 2023-06-30 | $64.73K 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |